Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
clinical trials
19
×
life sciences
national blog main
biotech
boston blog main
boston top stories
fda
national top stories
new york blog main
amgen
boston
deals
san francisco blog main
new york top stories
new york
san diego blog main
alnylam pharmaceuticals
drugs
eli lilly
inclisiran
investing
regeneron pharmaceuticals
san diego top stories
san francisco top stories
cholesterol
pcsk9 inhibitors
rare disease drugs
rna interference
roche
sanofi
alexion pharmaceuticals
alirocumab
blueprint medicines
calcitonin gene-related peptide
cancer
cancer drugs
chronic migraine
detroit blog main
detroit top stories
dyne therapeutics
What
drug
19
×
medicines
19
×
fda
ipo
new
therapeutics
cholesterol
approved
company
disease
genetic
lowering
medco
approval
cancer
lead
muscle
pharmaceuticals
rare
research
year
ago
alnylam
announced
biotech
brings
candidate
class
data
deal
developed
developing
diseases
dyne
long
medicine
migraine
million
nod
pain
Language
unset
Current search:
drug
×
" clinical trials "
×
medicines
×
@xconomy.com
3 years ago
Dyne’s Upsized IPO Brings In $233M for Muscle Disorders Drug R&D
@xconomy.com
3 years ago
Dyne Eyes IPO for R&D of Genetic Medicines for Rare Muscle Diseases
@xconomy.com
3 years ago
Roche, Blueprint Medicines Team Up Again in $775M RET Cancer Drug Pact
@xconomy.com
3 years ago
Goldfinch Raises $100M for Kidney Drug Studies Now, Perhaps an IPO Later
@xconomy.com
4 years ago
Esperion’s Combo Pill for Lowering Cholesterol Levels Wins FDA Nod
@xconomy.com
4 years ago
Revolution Medicines IPO Reels In $238M to Take On RAS in Cancer
@xconomy.com
4 years ago
Black Diamond Lines Up IPO as Lead Cancer Drug Nears Clinic
@xconomy.com
4 years ago
Novartis to Acquire MedCo and FDA-Ready Cholesterol Drug for $9.7B
@xconomy.com
4 years ago
Roche to Pay Dicerna Pharma $200M to Team Up on Hepatitis B Drug
@xconomy.com
4 years ago
UCB Stakes Out Autoimmune Territory With $2.1B Deal for Ra Pharma
@xconomy.com
4 years ago
MedCo Preps for FDA Filing as Cholesterol Drug Clears Last Two Tests
@xconomy.com
4 years ago
Frequency Plans IPO for Hearing Loss Drug & More Regenerative Meds
@xconomy.com
4 years ago
As Cholesterol Drug Aces Big Test, MedCo CEO Open to Flexible Pricing
@xconomy.com
5 years ago
MedCo Touts New Data for Long-Lasting Heart Drug as Reckoning Looms
@xconomy.com
5 years ago
FDA OKs Pfizer Rare Disease Drug, Sets Up Battle With Alnylam, Akcea
@xconomy.com
5 years ago
Qpex Biopharma Launches with $33M to Tackle Drug-Resistant Infections
@xconomy.com
5 years ago
Eli Lilly Migraine Drug Approved, the Third in New Class of Medicines
@xconomy.com
6 years ago
Fixing the Clinical Trial Bottleneck by Making Patients a Priority
@xconomy.com
6 years ago
Amgen Migraine Drug Gets FDA Nod, First in New Class of Medicines